Breast tumors display remarkable biological and clinical heterogeneity as covered extensively in the Introduction and Progress Report. Developing a better understanding of the molecular basis of such heterogeneity is central to the goal of rational, individualized treatment for patients based on molecular profiling. A large number of pathways, including RTKs, RAF/MEK/ERK, AKT, NFKB, JAK/STAT, JNK, p38, etc. work to control diverse cellular processes. In cancer the aberrant activity of the system is responsible for proliferation, apoptosis and other """"""""hallmarks of cancer"""""""". Diverse open questions concerning both the basic biology of cancer signaling and related therapeutic implications are rooted in tumor-specific network connectivity. The need to elucidate such tumor specific connectivity motivates the broad goals of this project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112970-10
Application #
8629530
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
10
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Riesco, Adrián; Santos-Buitrago, Beatriz; De Las Rivas, Javier et al. (2017) Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search. Biomed Res Int 2017:1809513
Hassan, Saima; Esch, Amanda; Liby, Tiera et al. (2017) Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther 16:2892-2901
Sears, Rosalie; Gray, Joe W (2017) Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Cancer Discov 7:131-133
Gendelman, Rina; Xing, Heming; Mirzoeva, Olga K et al. (2017) Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells. Cancer Res 77:1575-1585
Hafner, Marc; Heiser, Laura M; Williams, Elizabeth H et al. (2017) Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci Data 4:170166
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134
Hill, Steven M; Nesser, Nicole K; Johnson-Camacho, Katie et al. (2017) Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst 4:73-83.e10
Seviour, E G; Sehgal, V; Mishra, D et al. (2017) Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene 36:1339-1350

Showing the most recent 10 out of 193 publications